| Heavy Rare Earths Limited (HRE) ORDINARY FULLY PAID |
Materials |
$10 |
HRE December 2024 Quarterly Activities Report & Appendix 5B
|
30 Jan 2025 8:25AM |
$0.025 |
$0.048 |
risen by
92%
|
|
HRE - Price-sensitive ASX Announcement
Full Release
Key Points
- HRE acquired uranium exploration assets from Havilah Resources Limited.
- The transaction involves earning an 80% interest by spending $3 million over three years.
- Exploration efforts commenced at Lake Namba-Billeroo and Prospect Hill projects.
- Geophysical surveys are being conducted to identify palaeochannels.
- High assay results from Radium Hill confirmed the presence of U, REE, and Sc.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$32 |
NAOS Quarterly Investment Report - Q2 FY25
|
30 Jan 2025 8:25AM |
$0.405 |
$0.690 |
risen by
70.37%
|
|
| Galileo Mining Ltd (GAL) ORDINARY FULLY PAID |
Materials |
$53 |
Quarterly Activities Report December 2024
|
30 Jan 2025 8:25AM |
$0.145 |
$0.270 |
risen by
86.21%
|
|
GAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Exploration expenditure during the December 2024 Quarter was $662,000.
- No substantive mining production and development activities occurred during the Quarter.
- Galileo Mining remains well-funded with approximately $11.3 million in cash.
- 5,300 meters of aircore drilling completed at the Mission Sill prospect.
- Significant PGE assay results were reported from the drilling campaign.
- Follow-up drilling is scheduled for late February 2025.
- Joint Ventures with the Creasy Group continue on Fraser Range tenements.
- Galileo held its Annual General Meeting on 24 October 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MYECO Group Ltd (MCO) ORDINARY FULLY PAID |
Materials |
$11 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:25AM |
$0.020 |
$0.019 |
fallen by
5%
|
|
MCO - Price-sensitive ASX Announcement
Full Release
Key Points
- Total sales of sustainable products increased by 32.0% to $4.1 million in Q2 FY25
- Record global sales of MyEco branded products rose by 155.8% to $1.6 million in Q2 FY25
- Gross margins improved to 26.3% from 19.3% in Q1 FY25
- Cash balance of MyEco Group was $3.55 million as of December 31, 2024
- Net operating cash flows were negative $1.4 million in Q2 FY25
- Strong sales growth is expected to continue in the second half of FY25
- MyEco Group ceased trading in traditional plastics and recorded no sales in this sector for Q2 FY25
- Sustainable resin sales were down 41.5% in Q2 FY25
- Sales to council and waste management sectors increased by 55.1% on prior corresponding period
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$50 |
NAOS Quarterly Investment Report - Q2 FY25
|
30 Jan 2025 8:25AM |
$0.410 |
$0.380 |
fallen by
7.32%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,671 |
Net Tangible Asset Backing
|
30 Jan 2025 8:24AM |
$2.850 |
$4.220 |
risen by
48.07%
|
|
| Capricorn Metals Ltd (CMM) ORDINARY FULLY PAID |
Materials |
$6,747 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2025 8:24AM |
$7.580 |
$14.790 |
risen by
95.12%
|
|
CMM - Price-sensitive ASX Announcement
Full Release
Key Points
- Capricorn produced 28,702 ounces of gold in Q2 2025.
- Total half-year production is 54,261 ounces.
- The company is on track to achieve FY25 guidance of 110,000 to 120,000 ounces.
- Cash costs before royalties were $1,272 per ounce.
- All-in sustaining costs (AISC) were $1,490 per ounce.
- Exploration drilling included 30,627 metres completed across MGGP.
- Capricorn acquired the Sylvania Project, enhancing its strategic holdings.
- Plans for KGP expansion include a new three-stage crushing and milling circuit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rox Resources Limited (RXL) ORDINARY FULLY PAID |
Materials |
$777 |
Change in substantial holding
|
30 Jan 2025 8:24AM |
$0.210 |
$0.560 |
risen by
166.67%
|
|
| Beforepay Group Limited (B4P) ORDINARY FULLY PAID |
Financials |
$95 |
Q2FY25 Quarterly Activities and Appendix 4C Cash Flow Report
|
30 Jan 2025 8:24AM |
$1.570 |
$1.915 |
risen by
21.97%
|
|
B4P - Price-sensitive ASX Announcement
Full Release
Key Points
- Q2 FY25 revenue exceeded $10 million.
- Net profit before tax achieved was $1.1 million.
- Total advances reached $205.6 million, a 13% year-on-year increase.
- Active users increased to 257,627.
- Operating expenses decreased to $3.6 million.
- Launched a new Personal Loan product.
- Cash balance reported at $18.3 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bio-Gene Technology Ltd (BGT) ORDINARY FULLY PAID |
Materials |
$11 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:24AM |
$0.053 |
$0.035 |
fallen by
33.96%
|
|
BGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Two competitive grants totaling A$3.0m awarded under the U.S. Deployed Warfighter Protection program.
- Expanded program with Envu to develop Flavocide formulations for mosquito management.
- Pilot-scale batches of Flavocide produced for regulatory safety studies.
- Thirteenth Qcide harvest completed with improved oil extraction efficiency.
- Intellectual property portfolio strengthened with six new patents granted.
- Cash balance of A$1.3m at the end of December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sandfire Resources Limited (SFR) ORDINARY FULLY PAID |
Materials |
$9,169 |
December 2024 Quarterly Report
|
30 Jan 2025 8:24AM |
$9.760 |
$19.850 |
risen by
103.38%
|
|
SFR - Price-sensitive ASX Announcement
Full Release
Key Points
- TRIF decreased to 1.6 at 31 December 2024.
- Mining authority approval received for a new tailings facility at MATSA.
- Group Copper Equivalent production increased by 5% to 75.1kt in H1 FY25.
- Sustained mining and processing rates in excess of 4.6Mtpa at MATSA.
- Reduced Motheo's Underlying Operating Cost guidance by 7% to $39/t of ore processed for FY25.
- Invested approximately $5M in regional exploration and $3M in resource extension exploration.
- Unaudited Group sales revenue of $290M and Underlying Operations EBITDA of approximately $153M in Q2 FY25.
- Cumulative reduction in net debt across nine months to 31 December was $193M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lark Distilling Co. Ltd (LRK) ORDINARY FULLY PAID |
Consumer Staple |
$65 |
December 2024 Quarterly Update and Appendix 4C
|
30 Jan 2025 8:24AM |
$1.130 |
$0.610 |
fallen by
46.02%
|
|
LRK - Price-sensitive ASX Announcement
Full Release
Key Points
- Net sales revenue grew by 7% to $4.5 million in Q2FY25.
- Direct-to-consumer sales drove growth, with a $0.3 million increase.
- International sales momentum included a 12% increase in Global Travel Retail net sales.
- Domestic B2B sales declined due to distribution challenges.
- Cash balance at 31 December 2024 was $23.6 million.
- Whisky bank remained stable at 2.5 million litres.
- Ongoing development of the Lark Portfolio & Brand restage.
- Bothwell Distillery sale process is progressing with a conditional offer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biome Australia Limited (BIO) ORDINARY FULLY PAID |
Consumer Staple |
$100 |
Positive Results on Clinical Development of BMB18
|
30 Jan 2025 8:24AM |
$0.655 |
$0.450 |
fallen by
31.30%
|
|
BIO - Price-sensitive ASX Announcement
Full Release
Key Points
- Biome has received positive results of core functional characterisation studies of its strain BMB18
- The strain demonstrated an ability to effectively modulate immune responses and inflammation
- BMB18 can reduce oxidative stress and maintain intestinal barrier integrity
- The study indicated potential benefits for chronic intestinal diseases and food intolerances
- BMB18's capability to reduce inflammation may help counter cardiovascular diseases and neurodegenerative disorders
- The Managing Director expressed optimism regarding the commercial potential and applications of BMB18
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Articore Group Limited (ATG) ORDINARY FULLY PAID |
Consumer Discretionary |
$103 |
Trading update
|
30 Jan 2025 8:24AM |
$0.265 |
$0.350 |
risen by
32.08%
|
|
ATG - Price-sensitive ASX Announcement
Full Release
Key Points
- Marketplace revenue continued to decline.
- Annualized savings of approximately $12 million to $14 million identified.
- FY25 operational expenditure is now expected to be between $89 million to $92 million.
- Gross profit after paid acquisition margin guidance increased to 25% - 27%.
- Positive underlying cash flow expected in FY25.
- New product Dashery launched for creators to sell print on demand merchandise.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Canterbury Resources Ltd (CBY) ORDINARY FULLY PAID |
Materials |
$11 |
Excellent Progress at the Briggs Copper Project
|
30 Jan 2025 8:24AM |
$0.021 |
$0.039 |
risen by
85.71%
|
|
CBY - Price-sensitive ASX Announcement
Full Release
Key Points
- Assay results confirm the Southern porphyry target as a new discovery.
- Higher-grade zones of mineralisation have been extended at the Central porphyry.
- The 2024 drilling program has outlined a higher-grade zone, enhancing early mining options.
- A Scoping Study for the project is scheduled for completion in mid-2025.
- Funding for the project continues to be provided by Alma Metals Ltd under an Earn-In Agreement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Australia Bank Limited (NAB) ORDINARY FULLY PAID |
Financials |
$133,038 |
Notification of cessation of securities - NAB
|
30 Jan 2025 8:23AM |
$39.490 |
$43.370 |
risen by
9.83%
|
|
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$54 |
Q2 FY25 Investor Presentation
|
30 Jan 2025 8:23AM |
$0.075 |
$0.078 |
risen by
4%
|
|
| Intelligent Monitoring Group Limited (IMB) ORDINARY FULLY PAID |
Industrials |
$280 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:23AM |
$0.470 |
$0.680 |
risen by
44.68%
|
|
IMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating cash flow pre-non-recurring items of $7.9 million for 1H2025
- Adjusted EBITDA guidance of over $38 million reaffirmed
- Completion of equity raise and acquisition of DVL
- Launching of ADT and Signature Guarding services on track
- Debt refinancing proceeding according to plan
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$54 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:23AM |
$0.075 |
$0.078 |
risen by
4%
|
|
CCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Q2 FY25 revenue of US$3.5 million, up 53% from the previous year.
- Customer receipts increased to US$3.7 million, a 103% rise on the prior corresponding period.
- 76% of FY25 year-to-date revenue is from recurring revenue streams.
- Active cards on the Vertexon PaaS platform rose to over 66,000.
- Exit from the loss-making US operations is expected to improve financial performance.
- The company aims for revenue growth exceeding 30% in FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$52 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2025 8:23AM |
$0.071 |
$0.143 |
risen by
100.70%
|
|
DOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Market guidance in the period was met, or exceeded.
- Revenue growth in H2 2024 was at the upper end of guidance range of 0-5%.
- DOC generated underlying positive cash flow in H2 2024.
- Achieved target gross margin of 55-60% in Q4 2024.
- £0.8m net cash inflow in Q4 2024.
- Consultations were down 2.2% QoQ.
- Exited quarter with £4.4m cash on hand.
- Financial guidance for 2025 will be shared with year end results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gold Road Resources Limited (GOR) ORDINARY FULLY PAID |
Materials |
- |
Becoming a substantial holder
|
30 Jan 2025 8:23AM |
$2.480 |
$3.480 |
risen by
40.32%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$105 |
Quarterly Activities & Cashflow Report
|
30 Jan 2025 8:23AM |
$0.180 |
$0.390 |
risen by
116.67%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- ISLA-101 shows safety and anti-dengue activity in the Phase 2a prophylactic trial.
- Phase 2b therapeutic arm commenced after Phase 2a data submission to the US FDA.
- Mr. Phillip Lynch appointed as Executive Chairman.
- A$3.5 million secured via a placement to fund clinical programs.
- Cash position of A$3.99 million as of 31 December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NGX Limited (NGX) ORDINARY FULLY PAID |
Materials |
$11 |
December 2024 Quarterly Report
|
30 Jan 2025 8:23AM |
$0.150 |
$0.125 |
fallen by
16.67%
|
|
NGX - Price-sensitive ASX Announcement
Full Release
Key Points
- NGX is developing a portfolio of African projects focused on clean energy minerals.
- Permitting for the Tubusis uranium exploration project in Namibia progressed significantly.
- Ongoing bulk-scale optimization testing for Malingunde's downstream processing.
- NGX is enhancing AAM production from high-quality natural graphite.
- Improvements in Malingunde's upstream operations lead to higher-purity graphite concentrate.
- Peter Fox appointed as Executive Director effective 2 December 2024.
- NGX holds approximately $4.8 million in cash and has no debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
MDR 4C 2Q FY25 Quarterly Update
|
30 Jan 2025 8:22AM |
$0.200 |
$0.022 |
fallen by
89%
|
|
MDR - Price-sensitive ASX Announcement
Full Release
Key Points
- 2Q FY25 operating revenue down 38.6% to $30.8 million.
- US revenue decreased by 43.7% primarily due to deferrals in vaccine-related health programs.
- ANZ revenue increased by 1.9% to $5.4 million.
- Gross profit margin improved by 8.4 percentage points to 63.6%.
- Business restructure initiated expected to save at least $5 million annually in FY26.
- Cash on hand as of 31 December 2024 is $12.4 million.
- A formal review process has begun to evaluate strategic options for maximizing shareholder value.
- Positive first half EBITDA guidance confirmed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VGI Partners Global Investments Limited (VG1) ORDINARY FULLY PAID |
Financials |
- |
Update - Notification of buy-back - VG1
|
30 Jan 2025 8:22AM |
$1.850 |
$1.950 |
risen by
5.41%
|
|
Call 1300 880 160
Start a chat
Schedule a call
